InSightec's ExAblate technology was selected as one of CIRSE 2014's hot topics of the year

CIRSE 2014: The Cardiovascular and Interventional Radiological Society of Europe- The Scottish Exhibition and Conference Center, Glasgow UK, September 13-17, 2014

News provided by

InSightec

Sep 11, 2014, 08:00 ET

HAIFA, Israel, Sept. 11, 2014 /PRNewswire/ -- InSightec, a world leader in MR-guided Focused Ultrasound (MRgFUS) is proud to announce that its ExAblate^® technology was selected as one of the 2014 Cardiovascular and Interventional Radiological Society of Europe's hot topics of the year.

CIRSE is the world's largest Interventional Radiology congress and will host more than 5,000 doctors, researchers and medical professionals, mainly radiologists and interventional radiologists. One of the main discussions will be around whether MRgFUS technology presents benefits beyond those offered by more established ablation modalities.

InSightec fully believes that its MRgFUS is a technology that is revolutionizing medicine as we know it. Current clinical evidence shows high success rates as well as a high safety profile. All these clear advantages drove leading physicians in many prominent medical facilities around the world to adopt InSightec's ExAblate^® offering.

Currently InSightec's technology is already used to treat uterine fibroids, bone metastases, brain tremor disorders (still investigational in the USA), and more. In addition, researchers around the world are currently utilizing InSightec's ExAblate^® technology to treat liver cancer, pancreatic cancer, prostate cancer, and breast cancer under research protocols. Treatments of additional indications are expected to be pursued in the future.

InSightec will sponsor a Satellite Symposium: "MR guided Focused Ultrasound from Head to Toe. The symposium will be held Sept. 14, 13:00-14:00, in Auditorium 5. The session is going to be moderated by Mario Bezzi, MD and is going to be an especially interesting one as it will present clinical case studies shared by InSightec customers:

Tumour Ablation: Breast, Pancreas and Prostate - A. Napoli, MD (Rome, Italy)
Pain Palliation in Bone: Tumours and Facet - M. Dux, MD (Frankfurt, Germany)
Uterine Fibroids MRgFUS: Familiar Concept, New Evidence, MD - M. Matzko (Dachau, Germany)

In addition, CIRSE's Scientific Program Deputy Chairperson, Christopher Binkert, will lead a roundtable discussion on future applications of the technology.

We invite you to attend the session as well as visit us at the InSightec booth (#95) to learn more about our unique non-invasive technology for treating a variety of inner-body clinical indications.

ABOUT INSIGHTEC

INSIGHTEC is a world leader in MR-guided Focused Ultrasound (MRgFUS). The company, founded in 1999, has developed a completely non-invasive therapy platform that transforms medicine in an expanding number of neurosurgery, oncology and gynecology indications. MRgFUS is already adopted and used by world recognized physicians in more than 120 leading medical facilities around the world, who see the tremendous clinical and economical value of the InSightec therapy platform.

The company has received numerous awards for innovation from well-respected organizations including the Wall Street Journal, the European Union and TIME Magazine. The company is privately held by GE Healthcare, Elbit Imaging, York Capital Management and MediTech Advisors. For more information please visit: www.insightec.com

Media Contact

Xen Mendelsohn Aderka
VP of Marketing
INSIGHTEC
[email protected]
+972-4-8131309

SOURCE InSightec